Edmund Graziani

Sevin Rosen Bayless Management Co (Sevin Rosen Bayless) is a venture capital firm founded in 1981. The firm is headquartered in Dallas, Texas.

The International Partnership for Microbicides develops products for the prevention of human immunodeficiency virus. The private company is based in Silver Spring, MD.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX.

Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge.

Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA.

The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco.

AH Capital Management LLC (AH Capital Management) is a venture capital firm founded in 2009 by Marc Lowell Andreessen and Ben A. Horowitz. The firm is headquartered in Menlo Park, California.

New York Studio School of Drawing Painting & Sculpture provides arts education services. It offers programs and courses where a student gets a certificate and master in fine arts degree. The company was founded on September 23, 1964 and is headquartered in New York, NY.

Duke Comprehensive Cancer Center develops outpatient bone-marrow transplantation program. The company is headquartered in Durham, NC.

Braeburn Pharmaceuticals SPRL develops and commercializes medical products. It’s a pharmaceutical company focused on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. The firm offers Probuohine, CAM2038q1w, CAM2038q4w and Risperdone implant. The company was founded in 2012 and is headquartered in Road Town, British Virgin Islands.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.

CleanSlate Centers, Inc. operates addiction treatment center. It offers drug treatment, alcohol treatment, and treatment for multiple addictions. The company was founded by Amanda Wilson in 2009 and is headquartered in Northampton, MA.

Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA.

Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA.

The Mark Foundation for Cancer Research is a charitable organization that partners with scientists worldwide to accelerate research for the prevention, diagnosis, and treatment of cancer. The Mark Foundation is based in New York, NY and was founded by Alexander Mark Knaster. The foundation has awarded over $200 million in grants to more than 100 academic institutions across 13 countries since 2017. The non-profit company's research programs focus on early career support, team science collaboration, new technology innovation, and therapeutics discovery. The foundation also invests in early-stage cancer diagnostics and therapeutics companies.

Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA.

Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky.

Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY.

Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY.

Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA.

Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA.

Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation.

Intergalactic Therapeutics, Inc. is a gene therapy company based in Baltimore, MD. The company is revolutionizing gene therapies with a novel non-viral platform comprised of its versatile synthetic and episomal c3dna molecules. The company uses a customized approach to focal therapeutic delivery using its lead delivery technology, the comet pulsed electric field system, and a proprietary cell-free manufacturing process invented to make gene therapy safer and more accessible for patients. With programs in ophthalmology, oncology, respiratory diseases, and expansion areas including CNS, renal, and musculoskeletal, Intergalactic Therapeutics is dedicated to transforming genetic medicine. The company was founded by Michael D. Ehlers, and Theresa G. H. Heah has been the CEO of the company since 2023.

Evercrisp Biosciences, Inc. is a biotechnology company that focuses on the discovery and development of protein-based genome editors as therapeutics for multiple disease areas. The company is based in New York, NY.

Adendra Therapeutics Ltd. is an emerging British biotechnology company that was founded in 2021 as a spin-out of the Francis Crick Institute. The company is based in London, UK. The company is focused on discovering and developing new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases, building on new insights into dendritic cell biology. The company was founded in 2021 by Caetano Reis E Sousa, Raj Mehta. Raj Mehta has been the CEO since 2021.

Deep Apple Therapeutics, Inc. engages in a robust and promising pipeline of programs in inflammatory and immune diseases and metabolic & endocrine disorders. The company is based in New York, NY. The company was founded by Spiros Liras, John Irwin, Georgios Skiniotis, Brian Shoichet. Spiros Liras has been the CEO since incorporation.

Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation.

The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra.

Vicinitas Therapeutics is located in the US. Vicinitas Therapeutics is an American US-based biotechnology company that specializes in developing next-generation disease therapies using targeted protein stabilizers called Deubiquituinase Targeting Chimeras (DUBtacs). The company's mission is to solve critical problems in human health by developing disease therapies against an entire class of previously inaccessible disease-causing proteins.